Hubei Biocause Heilen Pharmaceutical Co., Ltd. / Fundamental strength relative to industry (Mohanram G-Value)
The G-Value, developed by Mohanram in 2005, is a measure of a fundamental strength for growth companies. According to Mohanram, a low G-Value suggests a higher probability that a stock may be overvalued relative to its growth potential due to hype or overexcitement. The approach is described in detail in Mohanram's 2005 Paper Separating Winners from Losers among LowBook-to-Market Stocks using Financial Statement Analysis.
- Fundamental strength relative to industry (Mohanram G-Value)
-
0 / 7
- Return on assets (ROA) greater than industry median
- close 2.6% ≤ 2.6%
- Operating cash flow over total assets greater than industry median
- close 0.7% ≤ 0.7%
- Operating cash flow greater than net income
- close $2.09M ≤ $7.67M
- Variance in ROA over the last 5 years less than industry median
- close 0.5% ≥ 0.5%
- Variance in year-over-year sales growth over the last 5 years less than industry median
- close 1,167.2% ≥ 1,167.2%
- R&D expenses over total assets greater than industry median
- close 1.1% ≤ 1.1%
- Capex over total assets greater than industry median
- close 5.4% ≤ 5.4%
G-Value history
The G-Value is calculated for each quarter based on the cumulation of the previous four quarterly statements. Click on the chart to see the G-Value at a specific time in the past.
-
0
-
0
-
0
-
1
-
1
-
1
-
1
-
1
-
1
-
1
-
1
-
0
-
0
-
0
-
0
-
0
-
0